Kingmed Diagnostics(SH:603882)2018-10-25 16:00Financial Performance - Operating revenue for the first nine months reached CNY 3,317,498,551.76, an increase of 18.48% compared to the same period last year[6] - Net profit attributable to shareholders was CNY 137,795,091.87, reflecting a growth of 12.33% year-over-year[7] - The company's net profit increased by 33.01% to CNY 509,000,260.00, driven by operational growth[14] - The company reported a total profit of 95,743,397.50 CNY for the first nine months of 2018, compared to 86,249,892.41 CNY in the same period of 2017, an increase of 6.83%[31] - Total operating revenue for Q3 2018 reached ¥1,202,848,433.53, an increase of 20.1% compared to ¥1,001,100,447.39 in Q3 2017[29] - Net profit for Q3 2018 was 75,435,855.41 CNY, compared to 71,128,864.08 CNY in Q3 2017, representing an increase of 4.06%[32] Assets and Liabilities - Total assets increased by 18.15% to CNY 3,923,997,282.96 compared to the end of the previous year[6] - The company's total liabilities increased to CNY 2,053,989,135.01 from CNY 1,577,031,755.70, marking a growth of around 30.2%[22] - Total assets as of Q3 2018 amounted to ¥2,445,877,217.94, compared to ¥2,105,084,931.94 at the end of Q3 2017, reflecting a growth of 16.2%[26] - Total liabilities for Q3 2018 were ¥702,604,546.74, an increase of 29.6% from ¥542,112,430.02 in Q3 2017[26] Shareholder Information - Net assets attributable to shareholders rose by 7.48% to CNY 1,829,677,846.60 year-over-year[6] - The total number of shareholders reached 24,112 by the end of the reporting period[12] - The top shareholder, Liang Yaoming, holds 15.52% of the shares, with 71,068,209 shares pledged[12] Cash Flow - Net cash flow from operating activities increased by 63.53% to CNY 259,493,101.50 for the first nine months[6] - Cash inflow from operating activities for the period (January to September) reached ¥3,071,549,352.11, an increase of 21.5% compared to ¥2,527,620,229.02 in the same period last year[38] - Cash inflow from sales of goods and services for the period was ¥3,000,855,430.37, an increase of 21% from ¥2,479,512,814.94 in the same period last year[38] - Cash inflow from financing activities totaled ¥274,027,598.86, a decrease from ¥590,982,400.00 in the previous year[40] Investments - Long-term equity investments surged by 1677.15% to CNY 83,640,063.82, primarily due to additional investments in DRA Company Limited[14] - The company plans to invest CNY 150 million in DRA Company Limited for a 50% stake in the high-end non-invasive prenatal testing (NIPT) sector[16] - The company has completed an investment of CNY 80 million in DRA Company Limited, acquiring a 34.78% stake[16] Operational Metrics - Basic earnings per share decreased by 5.26% to CNY 0.36 compared to the same period last year[7] - The weighted average return on net assets decreased by 3.36 percentage points to 9.21%[7] - Research and development expenses for Q3 2018 were ¥76,249,994.84, a rise of 16.9% compared to ¥65,357,674.80 in Q3 2017[30] - Other income for Q3 2018 was 1,042,067.41 CNY, compared to 318,000.00 CNY in Q3 2017, an increase of 228.57%[35] Inventory and Receivables - Accounts receivable and accounts payable increased by 31.69% and 31.51% respectively, reflecting the expansion of the company's operating scale[14] - Inventory rose by 52.17% to CNY 143,410,178.54, attributed to the increased operational scale during the reporting period[14] - Accounts receivable rose to CNY 1,425,454,019.00 from CNY 1,082,436,976.92, indicating an increase of approximately 31.7%[20]